Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) (NCT05743244)
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic ฮฒ Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
๐ฉบ Plain-English Summary (8th-Grade Level)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Orange County โ Orange, California
Age range: 12 Years to 35 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Children's Hospital Orange County โ Orange, California
- Stanford University โ Palo Alto, California
- University of California- San Francisco โ San Francisco, California
- Barbara Davis Center at University of Colorado Anschutz Medical Campus โ Aurora, Colorado
- Yale University School of Medicine โ New Haven, Connecticut
- University of Florida โ Gainesville, Florida
- University of Miami โ Miami, Florida
- University of South Florida Diabetes Center โ Tampa, Florida
- Emory Children's Center โ Atlanta, Georgia
- University of Chicago โ Chicago, Illinois
- Indiana University โ Indianapolis, Indiana
- University of Louisville Pediatric Endocrinology โ Louisville, Kentucky
- Joslin Diabetes Center โ Boston, Massachusetts
- University of Minnesota โ Minneapolis, Minnesota
- The Children's Mercy Hospital โ Kansas City, Missouri
- UBMD Pediatrics โ Buffalo, New York
- Columbia University-Naomi Berrie Diabetes Center โ New York, New York
- Joslin Center at SUNY Upsate โ Syracuse, New York
- University of Pittsburgh โ Pittsburgh, Pennsylvania
- Vanderbilt University Medical Center โ Nashville, Tennessee
- University of Texas Southwestern โ Dallas, Texas
- University of Utah โ Salt Lake City, Utah
- Benaroya Research Institute โ Seattle, Washington
- Royal North Shore Hospital โ Saint Leonards, New South Wales
- Queensland Children's Hospital โ South Brisbane, Queensland
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial โ Atlanta, Georgia
- Safety of ENC-201-CED ENCRT โ Toronto, Ontario
- Teplizumab in Pediatric Stage 2 Type 1 Diabetes โ San Francisco, California
- Allogenic Islet Cell Transplantation โ Chicago, Illinois
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells โ Charleston, South Carolina
- Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes โ Stanford, California
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.